Recurrence · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes adverse events compared with pharmacological therapy alone (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surgery for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐surgical therapy for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life Mean AcroQoL score (0‐100) · adults with growth‐hormone secreting pituitary adenomas
Surgery alone showed no clear difference in health‐related quality of life Mean AcroQoL score (0‐100) compared with pharmacological therapy alone (low certainty).
1 finding from 1 review
Disease‐related complications Intubation difficulties requiring postponement of surgery · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes disease‐related complications Intubation difficulties requiring… compared with preoperative pharmacological therapy and surgery (very low certainty).
1 finding from 1 review
Recurrence · adults with growth‐hormone secreting pituitary adenomas
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Quality of life at 3 months · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms
It is very uncertain whether escitalopram changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of PTSD symptoms ‐ Clinician‐rated · adults experiencing acute traumatic stress symptoms
1 finding from 1 review
Dropouts due to adverse events · adults experiencing acute traumatic stress symptoms
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
1 finding from 1 review
PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms
It is very uncertain whether hydrocortisone changes PTSD rate at 3 months compared with placebo (very low certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Word retrieval · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with primary progressive aphasia (PPA)
1 finding from 1 review